INVOKANA® BENEFITS
Healthy blood sugar, healthy lifespan
By removing excess blood sugar through urine, Invokana® may mimic caloric restriction without limiting caloric intake, offering several longevity benefits:
- Shown to extend lifespan¹ in mice by mimicking caloric restriction
- May reduce inflammation² and oxidative stress³ associated with age-related disease
- May improve cardiovascular⁴ and kidney health⁵ and lower the risk of dementia⁶ and Parkinson’s⁷ by removing excess glucose
- May eliminate senescent “zombie” cells⁸, a leading driver of biological aging
- May encourage moderate weight loss⁹ of 2-4%⁹ total body weight by excreting an extra 360kcal per day¹⁰
*See cited studies below. SGLT2 Inhibitors have not been FDA approved for these uses, but there are multiple studies that have shown these benefits.
How does Invokana® work?
- Removes up to 50-80g of glucose daily¹¹
That’s equivalent to 2 or more cans of soda per day removed through urine. - Originally developed to treat type 2 diabetes
Invokana® is an SGLT2 Inhibitor that works by limiting glucose reabsorption in the kidneys. - Creates a steady caloric deficit
Through glucose excretion, patients taking Invokana® may burn up to an extra 360kcal per day¹⁰. - Activates nutrient-sensing longevity pathways
By mimicking caloric restriction, Invokana® may activate¹² mTOR, AMPK, and SIRT1. - Broad longevity benefits
Modulating these longevity pathways may offer broad longevity potential¹³, such as reduced risk of heart disease, improved kidney and liver health, better cognitive function, and moderate weight loss.
“The human data of SGLT2 Inhibitors is remarkable…
The impact on kidney failure, all-cause mortality, and heart failure is pretty impressive.”
– Dr. Peter Attia, The Peter Attia Drive Podcast
Why AgelessRx?
Personalized care guided by US-licensed clinicians
Protocols backed by our Stanford PhD-led Applied Sciences Team
Every treatment is science backed, clinically vetted, and clinician-reviewed.
100% online, ongoing check-ins, and free shipping
Our customers think we’re excellent
-
Karey
They really care about making peoples lives more healthy and productive. The medical staff goes above and beyond to ensure your happy with your prescriptions.
-
Terry
Been living with chronic pain for a few years. […] I have more energy, can stand for longer periods, sit down and get up with ease. I feel like I’m aging backwards and I’m so thankful!!!
-
Jennifer
I’ve been with AgelessRx for over a year, and the care I’ve received has made a huge difference in my life. I used to suffer from chronic inflammation and fatigue, but since starting treatment, my inflammation levels have improved by 90%. I have more energy and just feel like myself again.
-
Kimberly
The products are of excellent quality and work. I can feel a difference in my mood. It helped to improve my body function, and my labs are proof.
-
Kristina
I love this place! The doctors listen and are very responsive and are all about quality of life while also giving you power over your own health and wellness. Life changer for sure!
-
Bridgette
I love AgelessRx it has been a complete game changer for me honestly! I have a much better quality of life now that I have began taking LDN and their prices, customer service and selections are top notch!
Ready to get started?
Complete your free visit now.
- Clinically shown to extend lifespan in mice
- Supported by 10+ years of robust scientific evidence
- Taken once daily
- Free shipping and ongoing support
- Pause or cancel anytime
Code INVO749: $749 for first month & FREE medical evaluation ($799/month after)
You will be automatically billed & sent refills based on your plan
You can pause or cancel at any time before your next shipment
FAQs
What’s the difference between Invokana® and Brenzavvy®?
Both Invokana® and Brenzavvy® are SGLT2 Inhibitors that work the same way. The only difference is that Invokana® has an extended range of FDA-approved uses: while Brenzavvy® is FDA approved for type 2 diabetes, Invokana® is approved for type 2 diabetes and to reduce the risk of heart and kidney disease.
Invokana® has also been patented since 2013, with a wealth of scientific studies to support its extended uses. Though Brenzavvy® is a relatively new SGLT2 (FDA approved in 2023), it still shares the same mechanism of action and may show similar longevity benefits as research continues.
Why does Invokana® cost more than Brenzavvy®?
While Brenzavvy® has only been FDA approved since 2023, Invokana® has been patented since 2013, with a wealth of scientific studies to support its extended uses, which may explain its higher price.
AgelessRx provides Invokana® and Brenzavvy® at a competitive price according to what our pharmacy partners can source from the manufacturer. The prices listed on AgelessRx.com are out-of-pocket costs and are not affected by insurance: AgelessRx does accept insurance for Invokana® or Brenzavvy® and does not treat or manage type 2 diabetes or any other FDA-approved condition for SGLT2 Inhibitors.
How do you take SGLT2 Inhibitors?
Invokana® (Canagliflozin) and Brenzavvy® (Bexagliflozin) are both oral medications, taken by mouth once per day. Simply swallow each dose with a glass of water.
Both should be taken in the morning, before the first meal of the day. Please note that some patients may have to split their Invokana® tablets to take their prescribed dose.
Why should I take SGLT2 Inhibitors in the morning?
Taking SGLT2 Inhibitors in the morning is a dual strategy for decreasing the chances of excessive nighttime urination and to avoid potential glucose spikes from your meal.
SGLT2 Inhibitors may increase urination, which can interrupt sleep if the medication is still active during bedtime. These medications can also delay glucose absorption, which can reduce glucose spikes from your first meal.
What if I miss a dose of SGLT2 Inhibitors?
SGLT2 Inhibitors are taken daily in the morning, before the first meal of the day. If it’s still morning and you haven’t had your first meal of the day, you can take the medication as normal. If morning has passed or you’ve already had breakfast, skip the dose you missed and take your dose the next morning.
See all FAQsImportant safety information and common side effects
Most common side effects
The most common side effects of SGLT2 Inhibitors include increased urination, dehydration, hypotension (low blood pressure), dizziness, urinary tract infections (UTIs), and genital mycotic infections (yeast infections). Increased urination is a normal side effect of SGLT2 Inhibitors and not cause for concern.
UTIs and yeast infections are among the most frequently reported side effects of SGLT2 Inhibitors. To reduce the risk of these and other side effects, drink plenty of water throughout the day (around 0.5 to 1 gallon) and follow proper genital hygiene practices. If you experience a UTI or yeast infection, you must seek treatment with your primary healthcare provider or a local urgent care clinic.
If you notice side effects other than increased urination, it’s okay to stop taking the medication until side effects clear—usually after a few days and up to a few weeks. Always let your prescriber know if you stop your medication so they can adjust your upcoming refills if necessary.
Serious side effects include euglycemic diabetic ketoacidosis (eDKA), Fournier’s gangrene, and acute kidney injury. These side effects typically occur in patients with diabetes or compromised kidney function. Please tell your prescriber if you or anyone in your family has diabetes or compromised kidney function, or any other medical condition. AgelessRx does not manage or treat diabetes.
The above is not an exhaustive list. Please review Cleveland Clinic’s resources for Invokana® (Canagliflozin).
Potential drug interactions
Please inform your AgelessRx prescriber of all medications you are taking, including supplements and over-the-counter medications.
Invokana® (Canagliflozin) should not be used by anyone taking insulin, sulfonylureas (Amaryl, Glucatrol, Micronase, etc.), or digoxin (Digox, Lanoxin).
Those taking colchicine (Mitigare, Colcrys) must stop taking the medication at least 72 hours before starting Invokana®.
Other important safety information
Invokana® should not be taken by anyone with the following conditions:
- Type 1 diabetes
- History of diabetic ketoacidosis
- Severe peripheral vascular disease
- History of amputation
- History of pancreatic impairment
- Active cancer
- Pregnant or breastfeeding
Your prescriber may ask you for additional information if you have one of the following conditions:
- Types 2 diabetes
- Renal impairment
- High AST/ALT ratio
- Abnormally high or low blood pressure
- Low-carbohydrate or ketogenic diet
Though rare, allergic reactions to Invokana® (Canagliflozin) are still possible. If you notice any shortness of breath or swelling around your face, tongue, or throat after using Invokana®, stop use and contact emergency services right away.
As with any medication, the dose prescribed is for you and you alone. Do not, under any circumstances, allow anyone else to use your Invokana® prescription.
Note: This product alone is not intended to diagnose, treat, cure, or prevent any disease. Please consult a medical professional to determine whether or not Invokana® is right for you.
Gatekeeping is so traditional healthcare
We read the clinical trials so you don’t have to. Here’s all the science behind our claims.
| 1. This study tested whether Canagliflozin (Invokana®) can extend life in mice, as part of the Interventions Testing Program, concluding that male mice had improved lifespan | JCI Insight, 2020 |
| 2. A review study monitoring the impact of Canagliflozin (Invokana®) on diabetic kidney disease based on the biodata of 296 participants, with observed reductions in inflammatory markers such as IL-6. | Diabetologia, 2019 |
| 3. This study investigates the therapeutic potential of Canagliflozin (Invokana®) on diabetic mice and how it can mitigate inducers of diabetes, like oxidative stress. | Front Endocrinol (Lausanne), 2022 |
| 4. A review study exploring the effects of Canagliflozin (Invokana®) on cardiovascular risk factors in patients with type 2 diabetes. | Int J Clin Pract, 2017 |
| 5. The CREDENCE trial, funded by Janssen Research and Development, tracks renal (kidney) outcomes on patients with type 2 diabetes taking Canagliflozin (Invokana®). | NEJM, 2019 |
| 6. This study followed patients who were at risk of dementia to determine if those taking SGLT2 Inhibitors developed dementia at a lower rate than those taking a DPP-4 inhibitor. | BMJ, Aug 2024 |
| 7. The first large-scale trial directly comparing whether SGLT2 Inhibitors or Metformin offer greater neuroprotection against Parkinson’s disease. | J Parkinson Dis, 2025 |
| 8. A clinical study using animal models to determine whether SGLT2 Inhibitors eliminate senescent cells. | Nature Aging, 2024 |
| 9. A combined weight loss study of 334 overweight or obese participants taking Canagliflozin (Invokana®), phentermine, both medications, or placebo, with patients in the Canagliflozin group losing an average of 3.6% of total body weight after 26 weeks. | Diabetes Care, May 2017 |
| 10. A double-blind, placebo-controlled trial measuring the impact of empagliflozin, an SGLT2 Inhibitor, on dietary energy restriction in 68 adults with type 2 diabetes. | Diabetes Obes Metab, 2022 |
| 11. A review study exploring the total renal glucose reabsorption of SGLT2 Inhibitors in humans. | Diabetes, Aug 2012 |
| 12. This review study explores the available peer-reviewed evidence for the ability of SGLT2 Inhibitors to target aging pathways. | Int J Mol Sci, 2022 |
| 13. General prescriber information for SGLT2 Inhibitors. | National Library of Medicine |